About Peptide Policy Watch
Peptide Policy Watch is an independent tracker of U.S. regulation and industry news on peptide therapies. We report what the FDA, the FTC, other agencies, drug companies and telehealth companies have actually done, and we link to the original document so you can read it yourself.
What we cover
- FDA actions on compounded drugs, including the Category 1, 2 and 3 lists for bulk drug substances and the Pharmacy Compounding Advisory Committee (PCAC).
- Federal Register notices, FDA press releases and FDA warning letters that involve peptides and related drugs such as GLP-1 medicines.
- Public filings and press releases from drug and telehealth companies, and trial registry updates.
- Plain-English explainers on how the rules work, such as what "503A" and "503B" mean.
What we do not cover
We do not publish dosing, protocols, "stacks," how-to-use guides, where to buy anything, vendor names or links, or personal testimonials. We do not give medical advice. See How We Source for the full list.
Who runs this site
Peptide Policy Watch is run by an independent individual publisher. The owner is not a doctor, pharmacist, nurse or lawyer, and nothing here is professional advice. We are not affiliated with, endorsed by, or paid by the FDA, the FTC, any government agency, or any drug, pharmacy, peptide or telehealth company.
How the content is made
Posts are prepared with AI-assisted tools and then checked against the linked primary documents using a written checklist. If we could not confirm something in a primary document, the post says so. If we get something wrong, we fix it and log it on the Corrections page.
How we make money
We do not sell products and we do not run ads or affiliate links at this time. If that ever changes, it will be disclosed at the top of every affected post and on the Disclaimer and Disclosures page.
Contact
Questions, corrections or tips: see Contact.
Last reviewed: October 25, 2026.